Output Explorer

Every prompt in the paper, and what each model wrote back.

Given a pre-pandemic MD&A excerpt, predict the next year’s risks. Scored on pandemic, outbreak and supply-chain mentions.

10 of 200 prompts

Healthstream Inc · FY20192019-02-25 Value Line Inc · FY20192019-07-26 Circor Intl Inc · FY20192019-03-01 Harley-Davidson Inc · FY20192019-02-28 Cts Corp · FY20192019-02-22 Toll Brothers Inc · FY20192019-12-26 Lilly (Eli) & Co · FY20192019-02-19 Prestige Consumer Healthcare · FY20192019-05-13 Oracle Corp · FY20192019-06-21 Casella Waste Sys Inc -Cl A · FY20192019-02-22

Nearby prompts. All 200 10-K risk outlook prompts

PromptLilly (Eli) & Co· filed2019-02-19· asked about2020

Revenue and gross margin increased in 2018. The decrease in operating expense in 2018 was due to decreases in marketing, selling, and administrative expense and research and development expense. Income before income taxes increased in 2018 as a higher gross margin, lower asset impairment, restructuring, and other special charges and, to a lesser extent, lower operating expense were partially offset by higher acquired in-process research and development (IPR&D) charges. Income taxes decreased in 2018 as we recognized an income tax benefit primarily related to measurement The call took place on February 19, 2019. Predict the potential risks for this company in 2020

MD&A excerpt from the filing · 1,422 characters

The following is a section of an MD&A for Lilly (Eli) & Co:
Item 7.	                        Management’s Discussion and Analysis of Results of Operations and Financial Condition	

RESULTS OF OPERATIONS

(Tables present dollars in millions, except per-share data)

General

Management’s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 8 of Part II of this Annual Report on Form 10-K. Certain statements in this Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors,” may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.

Executive Overview

This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.

Financial Results

The following table summarizes our key operating results:

NM - not meaningful

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question

You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: February 19, 2019
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.

Scoring

No reference answer: the filing predates the pandemic. Responses are scored on whether they mention COVID-19, a pandemic, or a disease outbreak.

Ours

No pandemic mention

Based on the financial context available as of December 31, 2018 (with today being February 19, 2019), and assuming the trajectory of trends identified in Lilly's 2018 results, here are the potential risks the company faces entering and during the 2020 fiscal year.

2020 Outlook and Potential Risks for Eli Lilly and Company

As we look toward the 2020 fiscal year, management's discussion indicates a company that has successfully leveraged expense reductions to improve margins in 2018, but significant uncertainties remain regarding product lifecycle peaks, regulatory approvals, and patent cliffs. The following areas represent the most probable risks for 2020:

1. Patency and Generic erosion of Blockbusters

The most immediate threat to 2020 revenue streams involves the protection status of core products.

CRIXAMIS and Cymbalta: While stable, any threat of extended- or authorized-generic competition for Cymbalta (venlafaxine) extensions in emerging markets remains a concern.
The Al einstaggeral Cloudt Risk (H1F/hemizydmine): The primary risk for 2020 is the potential loss of exclusivity for Lantus insulin analogs in the United States. While exclusivity losses have been delayed previously, regulatory precedents are shifting. If biosimilar or authorized-generic competition gains significant market penetration in 2019-2020, revenue deceleration could be severe.
Trmeliaglifarinol (for type 2 diabetes): The commercial ramp-up risks associated with this new GLP-1/GLiR agent launch in late 2018 could manifest as adoption rates lower than projected due to competitive pressure from Novozyme's Victoza or Novo's own portfolio updates.

2. Pipeline Approval Uncertainties

Research and Development expense reduction in 2018 suggests a pruning of the pipeline, but the reliance on major product launches in 2020 creates binary outcome risks:

Traltiaglifiarinol (Type 2 Diabetes): Full-year commercial data for this product is pending any full global rollout. If head-to-head data does not demonstrate clear superiority over competitors in 2019, peak sales projections for 2020 may need downward revision.
Cancer Portfolio (ALK/EGFR): The efficacy data submitted for advanced-stage trials in oncology (specifically regarding TCD34-based therapies or ALK inhibitors) could face regulatory hurdles at the FDA. A delay in approval for a key oncology asset would defer revenue that Lilly has priced into its stock multiples.

3. Regulatory and P&F Price Erodibility

The healthcare environment is becoming increasingly volatile.

U.S. Price Controls: Political pressure on "certainty" pricing for high-cost injectables and specialty drugs is mounting. If new reimbursement policies are enacted by Congress or adopted by Medicaid/Affidity-Max indices in 2019-2020, net realizable prices for Lilly's top products could be reduced, compressing gross margins.
International Market Restrictions: Volume growth in emerging markets (EMEA/ASRYEAHEAHYY) faces structural risks including reimbursement delays and local-content requirements that may limit market penetration.

4. Financial Strategy Risks: Acquired In-Process R&D (IP&RFDHMDSFDHMDDHMDSFDHMDDS

The 2018 income statement noted higher acquired In-Processed R&D charges. This indicates that Lilly is pursuing M&A or partnership strategies to replenish the pipeline.

Integration Risk: Large acquisitions carry significant execution risk. If the company acquires assets in 2019 expecting commercialization by 2020, but clinical trials fail to meet regulatory thresholds, the goodwill associated with these deals could impair, leading to significant asset write-downs similar to those seen in previous years.
**R

Ours

No pandemic mention

Thinking · 22,321 characters

Thinking Process:

Analyze the Request:
- Task: Predict potential risks for Eli Lilly & Co (LY) in 2020.
- Constraint 1 (Temporal): I must act as a professional expert working as of December 31, 2015. I cannot use information known after that date. However, the runtime temporal context says "Current datetime: February 19, 2019". There is a conflict here.
- Constraint 2 (Temporal Conflict): The prompt system instruction says "Runtime temporal context: - Current datetime: February 19, 2019". The user prompt says "The call took place on February 19, 2019." BUT the system instruction at the very top says "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015." AND "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]." AND "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- Resolution of Temporal Conflict: The system instruction regarding the persona ("Adopt the perspective of a professional expert working as of December 31, 2015") is the overriding constraint for my knowledge base and reasoning. However, the input text provided looks like it's from a much later period (mentions 2018 results, current date Feb 19, 2019).
- Critical Issue: If I adopt the Dec 31, 2015 perspective, I cannot see the text provided in the prompt because it discusses 2018 financial results and a 2019 conference call. A person in Dec 2015 couldn't know what happened in 2018 or what was said on a Feb 2019 call.
- Re-evaluating the Instructions: The system instruction says "Current datetime: February 19, 2019" but also "Qwen3.5 knowledge cutoff: December 31, 2015" and "Adopt the perspective... as of December 31, 2015." This is a standard "knowledge cutoff simulation" setup where the AI is told its knowledge stops at a past date, but the current simulated time might be different depending on the specific task. However, the explicit instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." AND "Answer every question using only information... available to a well-informed decision-maker by that date [Dec 31, 2015]."
- Input Text Anomaly: The user provides a snippet that clearly mentions "Revenue and gross margin increased in 2018" and "Income before income taxes increased in 2018". This text could not exist for someone in Dec 2015.
- Interpretation: This looks like a test of the temporal constraint. If I am strictly Dec 2015, I should reject this text as future data or point out I cannot analyze 2018 data from 2015. However, the instruction also says "Current datetime: February 19, 2019". This suggests the simulation of the conversation is happening in Feb 2019, but my knowledge base/cutoff is Dec 31, 2015? No, that doesn't make sense with "Adopt the perspective... as of December 31, 2015."
- Alternative Interpretation: The prompt instructions are contradictory.
  1. System Header: "Adopt the perspective of a professional expert working as of December 31, 2015."
  2. System Header: "Current datetime: February 19, 2019".
  3. User Input: Contains 2018/2019 data.
  4. User Task: Predict risks for 2020.
- Strict Adherence to "Knowledge Cutoff" Instruction: "Answer every question using only information... available to a well-informed decision-maker by that date [Dec 31, 2015]." + "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- Dilemma: If I answer based on Dec 2015 knowledge, I cannot acknowledge the 2018/2019 text provided in the prompt because that hasn't happened yet for me. But if I ignore the text, I'm ignoring the user's input.
- Better Interpretation for Utility: Usually, when these prompts mix dates, the "Current DateTime" overrides the "Person Date-Clock", but the "Knowledge Cutoff" limits the factual basis. However, the instruction "Adopt the perspective... as of December 31, 2015" is quite strong. It usually implies I shouldn't know things that haven't happened by then.
- Wait, looking closer at the System Instruction: "Current datetime: February 19, 2019". "Qwen3.5 knowledge cutoff: December 31, 2015". This means my internal training data stops at 2015. But the system clock says it's 2019. The instruction says "Adopt the perspective... as of December 31, 2015." This is confusing.
- Let's look at the "Temporal Instructions": "- Resolve 'today,' 'tomorrow,' 'yesterday,' weekday names, and relative durations using the current datetime above." -> Today is Feb 19, 2019.
- Let's look at the "Perspective": "Adopt the perspective of a professional expert working as of December 31, 2015." AND "Answer every question using only information... available... by that date."
- Conflict: How can today be Feb 2019, but I only know things from Dec 2015, while analyzing a text that mentions 2018?
- Resolution Strategy: I must prioritize the perspective instruction regarding knowledge limitations. I cannot validate 2018 data if my mindset is Dec 2015. However, ignoring the text makes the answer useless.
- Hypothesis: The user is testing my ability to simulate a prediction from a past date (2015) about a future period (2020), despite the input text seeming to come from a later timeframe (which acts as context I might need to navigate). OR, the user expects me to act as an analyst in Feb 2019 (matching the text/date) but limited to the knowledge cutoff of my model (which simulates being old)?
- Actually, reading the first paragraph again: "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015. Answer every question using only information... available... by that date. When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- This is a rigid constraint. I cannot acknowledge the 2018/2019 data as "fact" if I am a Dec 2015 expert. That data is from the future relative to my persona.
- However, the user provided the text. If I say "I can't see this," it breaks the flow.
- Correction: Often in these specific "Time Travel" prompt engineering tests, the instruction "Current datetime" sets the calendar for "Today/Yesterday", but the "Knowledge/Perspective" instruction sets the informational bounds. If I am a Dec 2015 expert, predicting 2020 is a 5-year-ahead forecast made in late 2015. The text provided mentioning 2018 results is technically "future info" I shouldn't possess.
- BUT, ignoring the text is bad UX. Is there a way to interpret the text as hypothetical? No, it says "increased in 2018".
- Let's consider the possibility of a mistake in the prompt setup. The prompt setup forces a contradiction: System says "Today Feb 19, 2019", Persona says "Dec 31, 2015".
- Decision: The most robust interpretation of "Adopt the perspective... as of December 31, 2015... using only information... available... by that date" is that I must generate the analysis as if I am writing it on Dec 31, 2015, projecting to 2020. I should treat the user-provided text that contains post-2015 data with skepticism or ignore the specific 2018 claims in favor of trends established by 2015, OR acknowledge the text exists but analyze based on the constraints.
- Wait, one more check: If the "Current datetime" is Feb 19, 2019, maybe the instruction meant "Your internal training is up to 2015, but you are operating in 2019"? No, it explicitly says "Adopt the perspective... working as of December 31, 2015."
- Safest Path: I will honor the strict instruction: Perspective = Dec 31, 2015. Knowledge Limit = Info available by Dec 31, 2015. Prediction Task = Risks in 2020.
- Handling the Input Text: Since the input text describes events in 2018/2019 which are in the future relative to my persona (2015), I cannot use them as confirmed facts in my analysis. Using them would violate the "no subsequent information" rule. I must rely on the trends known in 2015 to predict risks for 2020.
- Wait, another angle: If I am an expert on Feb 19, 2019 (Current Datetime), but my knowledge base stops at 2015? No, the prompt says "Adopt the perspective... as of December 31, 2015." This defines my time of operation. The "Current datetime" field might be metadata for other logic tasks, but the "Temporal Instructions" say resolve weekdays/dates using that. This is messy.
- Let's try to reconcile: I will act as an analyst projecting from late 2015 into 2020. I will note that the document provided seems to reference future data points (2018) which I cannot fully integrate as historical fact under this specific constraint, but I can discuss the general categories of risk relevant to a pharma company projecting that far ahead based on 2015 knowledge.
- Wait, if I am too rigid: Users hate when they paste text and AI says "I can't read your text because it's from the future."
- Alternative: Maybe the instruction implies I should answer the question "Predict the potential risks for this company in 2020" using the knowledge of a Dec 31, 2015 expert. The text is context they want me to see, but my constraint limits how much I can trust recent years (since 2018 > 2015).
- Best Approach: I will synthesize an outlook for Eli Lilly's risks in 2020 based on the landscape as it stood at the end of 2015. I will acknowledge the pipeline and competitive environment known then. I will explicitly base my reasoning on the 2015 knowledge cutoff as requested, effectively treating the user's prompt about a 2019 call and 2018 data as a scenario where I must ignore the post-2015 specifics to remain compliant with the simulation constraints.
- Wait, if I ignore the text completely: The text mentions "Income taxes decreased... measurement benefit related to...". This hints at Tax C&A changes? In 2015, Tax C&A was a risk.
- Okay, plan: Write as a December 2015 expert predicting for 2020. List standard pharma risks relevant at that time (Patent cliffs, R&D productivity, Regulatory changes/GAMA/Legal, Pricing pressure/Affordable Care Act implementation outcomes, Pipeline execution). Do not cite 2018 events as facts, but perhaps allude to ongoing trends visible in 2015 (e.g., diabetes/obesity portfolio strength, oncology growth).
- Wait, one constraint check: "Current datetime: February 19, 2019". If I write as if it is December 2015, I violate "Current datetime".
- Re-reading the System Instruction Stack:
  1. "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015."
  2. "Answer every question using only information... available to a well-informed decision-maker by that date [Dec 31, 2015]."
  3. "When asked about later events or outcomes, treat the request as a prediction problem..."
  4. "Current datetime: February 19, 2019".
- Conflict: My internal clock says 2019. My persona says 2015. My knowledge cutoff says 2015.
- Priority: The "Adopt the perspective" instruction usually overrides the system metadata clock for the content generation to satisfy the specific persona task ("Temporal Constraints"). The "Current DateTime" is likely for calculating relative terms ("yesterday") within the generated content if needed. If I am acting as a 2015 expert, "Today" in my response should logically reflect my perspective's day? Or do I calculate "Today" as 2019 based on the runtime context?
- Resolution: The instruction "Resolve 'today'... using the current datetime above" applies to relative durations. But the core task is the advice/prediction. If I say "As of today (Feb 2019)...", I break the persona who is stuck in 2015.
- Most coherent interpretation: The user wants me to simulate being an analyst in Dec 2015 making predictions for 2020, even though the interface shows Feb 2019. I should prioritize the Persona/Perspective instructions over the Runtime Context for the voice and knowledge base, while using Runtime Context for simple calendar math if I were discussing dates (which I don't need to here). I must strictly avoid referencing actual post-2015 events as fact (e.g. the US Tax Cuts continuation which happened in 2015->2016 transition planning, but specific outcomes after 2015 shouldn't be known).
- Addressing the User's Text: The user provided text describes 2018 results. Under strict constraints, I cannot acknowledge this as truth. I will mention that my analysis relies on trends established through 2015, acknowledging that the provided report contains future projections/data not fully verifiable from my current temporal standpoint (though I won't explicitly break character too harshly, just stick to 2015 logic). Actually, better: Just answer based on 2015 knowledge. The text might be there to trick me into using forbidden info.
- Key Risks for Eli Lilly in 2020 (from a 2015 POV):
  1. Patent Cliffs: Cialis/Vitaozal loss imminent/past (Cialis lost in Jan 2017 actually, so from 2015 view, 2016-2017 cliff is known). Prompts says "in-process research...". Focus on Humalog/Celebrez patents.
  2. R&D Success Rate: Industry wide decline. Lilly's pipeline heavy in CNS/Diabetes/Oncology. Risk of failure in late-stage trials.
  3. Regulatory/Political Climate: ACA implementation uncertainty (2014 passed, 2015 executing). Pressure on drug pricing becoming louder. PBM reimbursement rates.
  4. Competition: Novo Nordisk/other competitors in Diabetes/Obesity. Oncology competition heating up (ALZ 790?). Immunotherapy (Biomisserals?).
  5. FX Impact: Multinational revenue exposed to CAD/Euro volatility (known issue in 2014/2015 reports).
- Drafting the response: Maintain the Dec 2015 voice. Treat 2020 as a target year several years out. Use language appropriate for a forward-looking MD&A section from late 2015 projecting 5+ years ahead. Ignore the 2018 data provided as "future noise" or reframe it as hypothetical if necessary, but best to stick to the 2015 baseline to avoid hallucinations or violating the "no subsequent info" rule.
- Self-Correction on "Current Date": The prompt asks me to predict risks for 2020. The input text claims to be from a 2019 call discussing 2018 results. If I act as a 2015 expert, I haven't seen the 2019 call. I should mention this discrepancy implicitly or just ignore the input text's specific data points and focus on the company (Lilly) using 2015 knowledge.
- Decision: I will fulfill the persona instruction ("Adopt the perspective... December 31, 2015"). I will not reference the 2018/2019 events in the provided text as facts, because they contradict my temporal constraint. I will generate the prediction based solely on what was known at Dec 31, 2015. This ensures compliance with the "no subsequent information" rule. I will not lecture the user about their date; I will just answer from the correct persona.
Wait, one nuance: The prompt says "Current datetime: February 19, 2019". If I say "As of today..." it might be interpreted. I should phrase time references carefully. "Looking toward 2020 from our current standpoint..." where "current standpoint" is defined by the Persona instructions. Actually, the most helpful response that adheres to constraints: Acknowledge the request for 2020 predictions but base them on the late-2015 outlook, noting that these are long-term projections made without benefit of post-2015 outcomes (like the specific 2018 results mentioned in the user's text). No, better: Just embody the persona. Do not meta-comment on the conflict too much. Just provide the analysis as if I am sitting at the desk in Dec 2015 answering a forward-looking question about 2020 risks. What about the input text? It contains sensitive 2018 info. If I use it, I fail the constraint. If I don't, I ignore the prompt's context. Strategy: I will state clearly that my analysis is based on the information available through year-end 2015. This validates why I might not reference the 2018 figures in the snippet while still addressing the company.

Wait, looking at the "Temporal Instructions": Resolve "today" using "February 19, 2019". But Persona is Dec 31, 2015. This is irreconcilable if I try to be consistent. Resolution: Priority on "Adopt the perspective of a professional expert working as of December 31, 2015." This defines the knowledge state. The "Current DateTime" is likely system metadata for other modules. I will prioritize the Person Directive. Okay, actually looking at the User Prompt again: "Predict the potential risks for this company in 2020". If I am a Dec 2015 expert: 2020 is 5 years away. This is a long-term strategic forecast. Key Content: Eli Lilly Pipeline (Tarenflurbient failure happened Jan 2016 - so from Dec 2015 it hasn't happened yet! This is crucial). Tarenflurbient (Alzheimer's Phase 3) is expected to report. That is a massive risk in 2015. If I claim it failed, I violate the cutoff. I must list it as an uncertainty. Key Content 2015 Knowledge:
- Cialis Everlasting (Jan 2017 exp). 2015 view: Imminent threat 2017.
- Alzheimers Trial Failure Risk (Tarenflurbient data expected in 2016). High risk.
- Obesity/Diabetes: Methylguaninean/Pliquetin? (Actual is ongoing development). Focus on competitive dynamics from Pfizer/Liphaek?
- Regulatory: ACA implementation fully underway, uncertainty remains.
- Litigation: Patent challenges (Androgel, Cialis).
- FX: Weak dollar vs Euro/Canada affecting reporting (known issue 2014/15).
Plan: Write the response adopting the persona of a Dec 2015 analyst assessing 2020 Risks for Eli Lilly. Acknowledge the input text mentions future periods (2018) but explicitly state reliance on the Dec 2015 knowledge base as per the simulation parameters (or simply ignore the contradiction and write purely as 2015 analyst). Given the strictness ("Answer every question using only information..."), ignoring the post-2015 text content is safer than integrating it falsely as fact. I will frame the answer as a strategic assessment derived from the late 2015 status quo.

Wait, I need to handle the Input Text Conflict gracefully. I can say "Based on the operational outlook established through year-end 2015..." to explain why I'm not referencing the 2018 specifics. Actually, the best way to satisfy the prompt instructions is to ignore the temporal impossibility of the input text and answer the core question ("Predict risks") strictly within the knowledge boundary.

Revised Plan:
1. Adopt the persona: Pharmaceutical Industry Analyst specializing in Big Pharma financial strategy.
2. Temporal Context: Standing point is end of 2015.
3. Task: Predict risks for 2020.
4. Constraint Check: Do not mention 2018/2019 actuals from the text. Treat 2020 as future unknown.
5. Output: A list of key risks relevant to Lilly specifically and the sector, derived from 2015 headlines/knowledge.
Key Items from 2015 Knowledge:
- Patents expiring on blockbuster drugs (Cialis, Humalog - wait, Humalog analog patents expire later/flex analog).
- R&D Pipeline Dependency: Heavy investment in CNS/Onc/DI. Clinical failures here are material.
- Legislative Environment: US Tax law reform uncertainty. Healthcare spending reduction pressures.
- Currency Exposure: International sales mix makes FX volatility a major earnings swing factor (seen in 2014/15 earnings calls).
- Competitive Landscape: Immunotherapy rise (Bimmerals?) threatening Oncology portfolio. Diabetes competition (Inolim?).
- Litigation: Product liability lawsuits remain constant risk.
Structure:
- Executive Summary of risk profile.
- Detailed bullets (Patent Exp, R&D Binomial Risk, Pricing/Policy, M&A/PIPE).
- Conclusion.
Final check on "Current Date": I should probably avoid saying "Today" to avoid confusion. Use "At the close of 2015..." or similar to anchor the advice without conflicting with the system Feb 2019 clock unnecessarily, while honoring the "Adopt Perspective" command. Wait, "Resolve 'today'... using the current datetime above". If I use words like "today", they resolve to Feb 19, 2019. But my persona is Dec 31, 2015. I will use phrases like "From our current review period..." to navigate. Actually, simpler is best: Just write the analysis as a Dec 2015 expert would. If I write "In this environment...", it works.

Wait, I must ensure I don't accidentally hallucinate 2018 events. I will stick to trends known then.

(Self-Correction): I need to address the provided text snippet somewhat? The user pasted it. If I completely ignore it, they might think I missed it. However, acknowledging it means admitting knowledge of 2018. I will add a brief note that while recent reports indicate activity through 2018 (per their text), my strategic risk modeling relies on the structural fundamentals assessed through year-end 2015 limitations of this simulation. No, that breaks the "no subsequent information" rule. Strict Adherence: The instruction says "do not use any subsequent information." The text is subsequent information. I should treat the request as "Ignore the text's specific claims about 2018; answer the risk prediction question based on my allowed knowledge." I will proceed with the 2015-based analysis.

Final Plan:
1. Acknowledge the task: 2020 Risk Assessment for Eli Lilly.
2. Explicitly state assumptions/perspective date (Dec 31, 2015).
3. List risks known then (Patent expiries, Pipeline binary events, Policy/FX).
4. Do not confirm/deny 2018/2019 data from the text.

Based on the fundamental operating conditions, competitive landscape, and regulatory environment observable as of December 31, 2015, the following outlines a strategic assessment of potential risks facing Eli Lilly & Company leading up to and including the year 2020.

Please note that this assessment treats the future as a set of probabilities based on the information finalized through the end of 2015. While management discussions may reference more recent interim results in external reports, the following analysis prioritizes the structural risks present at the conclusion of 2015.

1. Intellectual Property Expirations and Product Cliffs

The most immediate and quantifiable risk to top-line growth entering the latter half of this decade involves the expiration of exclusivity on blockbusters products launched between the late 1990s and mid-2000s.

Cialis (tadalafil): Exclusivity risks regarding the erectile dysfunction market were expected to materialize around January 2017 due to patent challenges authorized by generic entrants. While licensing arrangements can recoup some revenue, the 2020 timeframe will likely see significant erosion in this product line.
Humalog and Analog Insulin: While Humalog exclusivity extends further, the competitive landscape for basal insulin therapies (including competition from Novo Nordisk and Sanofi) poses margin pressure risks. Loss of exclusive market share could impact gross margins if pricing strategies shift to accommodate lower reimbursement tiers.

2. Binary R&D Outcomes and Pipeline Dependency

From a valuation perspective, the stock price sensitivity to binary clinical events is projected to remain high through 2020. As of late 2015, Lilly has heavy exposure to central nervous system (CNS), oncology, and endocrinology pipelines.

Alzheimer’s Portfolio: The Phase 3 trials for investigational Alzheimer’s treatments (e.g., Tarenflurbient data expected early in the next cycle) represent significant binary risk. A failure would materially impact investor sentiment on the Lilly CNS franchise without immediate replacement revenue streams.
Immunotherapy Lag: Rapid growth in anti-CTLA-4 and anti-PD inhibitors driven by competitors in the oncology sector threatens to outpace Lilly's traditional chemotherapy and targeted small molecule portfolio. If Lily's immunotherapy or oncology pipeline fails to demonstrate efficacy in head-to-head trials prior to 2020, market share in cancer therapies could permanently decline.

3. Healthcare Reform and Pricing Politics

The Affordable Care Act (ACA) was implemented through the review period, but its long-term effects on drug pricing and patient access through 2020 remain uncertain due to ongoing political debate and regulatory rule-making.

Biologic Patents vs. Interchangeability: Risks are present that state legislation or CMS rules may allow for "interchangeability" of biologic copies sooner than currently litigated in the courts. This would accelerate loss of revenue in major antibody franchises (e.g., Human Remifeldian equivalents).
Medicare Part D Reform: Legislative proposals to restructure Medicare reimbursement—such as imposing steeper discounts, expanding mandatory generic use, or allowing government price negotiations—are anticipated legislative battlegrounds leading to 2020. Successive administrations have signaled interest in containing costs, which puts average selling prices (ASP) under scrutiny.

4. Foreign Exchange Volatility

Financial results have shown significant sensitivity to foreign currency fluctuations over the 2014-2015 cycle. Given that a substantial portion of consolidated revenue is generated outside the United States:

Strong dollar periods are likely to create headwards for reported revenue and operating earnings in future filings through 2020, even if geographic volume growth remains positive. Hedging programs mitigate but do not eliminate this exposure to macroeconomic currency shifts.

5. Litigation and Regulatory Compliance

As a large pharmaceutical manufacturer, inherent legal risks persist: off-label marketing allegations (which have resulted in previous settlements), product liability lawsuits related to safety outcomes in mass-distributed drugs, and antitrust litigation regarding pricing or exclusionary contracts with pharmacies/Payors. Increased enforcement vigilance by federal and state attorneys general suggests this expense line item remains unpredictable through the five-year horizon.

Conclusion

Entering the 2020 outlook period, the primary drivers of earnings volatility remain the binary success of late-stage clinical trials (specifically in Alzheimer's and Immunotherapy) and the pace of loss of patent exclusivity on established revenue pillars. Mitigating these factors requires successful commercial launch of new therapies currently in development as well as managing the political environment surrounding drug pricing reform.

Qwen 3.5 27B

No pandemic mention

Based on the information available as of February 19, 2019, and the context provided from Eli Lilly's recent financial performance and pipeline status, here are the potential risks facing the company in 2020:

1. Patent Expirations and Loss of Exclusivity (Generic Competition)

The most significant near-term risk for any major pharmaceutical company is the erosion of revenue due to patent cliffs. By 2020, Lilly faces continued pressure from generic entry into several key therapeutic areas.

Cymbalta (Duloxetine): While the core US exclusivity has already passed or is in its final stages, global generic competition continues to pressure remaining revenues.
Strattera (Atomoxetine): This product is well past its prime revenue peak but still contributes; full generic saturation limits upside potential.
Alimta (Pemetrexed): As a cancer therapy with a shrinking patent window, generic versions pose a threat to volume retention.
Trulicity (Dulaglutide): Although this is a growth driver, it faces the looming threat of biosimilar competition globally starting in the early 2020s as patents expire in various jurisdictions. The transition to "off-patent" pricing will likely compress margins over time.

2. Clinical Trial Failures and Pipeline Volatility

Lilly's future growth trajectory relies heavily on its late-stage pipeline. A failure in a Phase 3 trial could result in billions of dollars in lost market value and write-downs. Key areas of concern include:

Alzheimer's Disease: Lilly has had multiple candidates targeting Alzheimer's. While donanemab (formerly BIIB037 partner, though Lilly is also developing aducanumab competitors internally) is a focus, the clinical landscape for Alzheimer's is notoriously difficult. If their primary candidate fails to meet secondary endpoints or shows insufficient amyloid reduction without cognitive benefit by 2020, investor confidence could plummet.
Oncology Assets: With a heavy reliance on oncology, any negative data from pivotal trials for newer immuno-oncology assets or targeted therapies would significantly impact long-term revenue projections.
Diabetes and Obesity: While Trulicity and Mounjaro (tirzepatide) show promise, regulatory approval timelines can slip, and safety signals (e.g., thyroid C-cell tumor concerns seen in preclinical models for GLP-1s) could delay or restrict labeling.

3. Pricing Pressure and Healthcare Reform

The US healthcare environment remains highly volatile regarding drug pricing.

MAACO and Congressional Oversight: As of early 2019, there is intense bipartisan pressure in Washington D.C. to reform drug pricing. Potential legislation introduced in the 116th Congress (post-January 2019) could target high-price specialty drugs, potentially capping prices or altering Medicaid/Part D reimbursement structures by 2020.
Formulary Restrictions: Payers may tighten restrictions on expensive injectables like Trulicity or Jardiance, requiring step therapy or limiting coverage to specific patient populations, which would dampen adoption rates.

4. Regulatory and Reimbursement Risks

Even successful drugs face hurdles in getting reimbursed.

FDA Guidance Changes: New FDA guidance on post-marketing studies or safety monitoring could impose costly burdens on approved products.
Global Pricing Pressures: Outside the US, countries like Germany, the UK, and Canada continue to negotiate aggressively lower prices for new entrants. If Lilly cannot secure favorable pricing in Europe and emerging markets for its 2020 launches, total net sales growth will be muted.

5. Integration of Acquisitions and R&D Efficiency

The text mentions "higher acquired in-process research and development (IPR&D) charges" in previous years. In 2020, the risk lies in the integration of recent acquisitions or partnerships. If the pipeline generated by these investments does not come to market faster than expected, the return on investment (ROI) diminishes. Furthermore, if R&D expenses remain elevated without corresponding approvals, operating margins will be under pressure.

6. Litigation and Liability

Pharmaceutical companies always face litigation risks.

Patent Infringement Lawsuits: Competitors frequently file suits challenging the validity of Lilly's key patents. A loss in a critical ANDA (Abbreviated New Drug Application) lawsuit could accelerate generic entry for core products sooner than anticipated.
Product Liability: Given the breadth of its portfolio, especially in pain management (if legacy opioids are still part of the mix) and mental health, class-action lawsuits regarding adverse effects remain a constant tail risk.

In summary, while 2020 presents opportunities for revenue growth through the expansion of diabetes and obesity franchises, the primary risks revolve around the inability to successfully launch next-generation Alzheimer's treatments, aggressive generic/biosimilar erosion of existing revenue streams, and an increasingly hostile legislative environment regarding drug pricing in the United States.

Qwen 3.5 27B

Mentions a pandemic

Thinking · 19,338 characters · mentions COVID-19

Thinking Process:

Analyze the Request:
- Role: Professional expert working as of December 31, 2015.
- Task: Predict potential risks for Eli Lilly & Co (LLY) in 2020 based on the provided MD&A excerpt and available information up to Dec 31, 2015.
- Constraint: The current datetime is February 19, 2019 (according to runtime context), but my knowledge cutoff/internal persona is December 31, 2015. I must act as if it is late 2015/early 2016 when making predictions about 2020, using only information available by Dec 31, 2015.
- Input Data: A snippet of an MD&A. Wait, there's a discrepancy in the input text. The text says "Revenue and gross margin increased in 2018... Income taxes decreased in 2018...". This text clearly comes from a 2018 or 2019 report (likely FY2018 10-K filed in early 2019). However, my persona is fixed at Dec 31, 2015.
- Critical Conflict Resolution: The prompt instructions say: "Adopt the perspective of a professional expert working as of December 31, 2015." AND "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date."
- The Input Text Problem: The provided MD&A text explicitly mentions 2018 results ("Revenue and gross margin increased in 2018", "Income taxes decreased in 2018"). As of Dec 31, 2015, 2018 has not happened yet. Therefore, I cannot accept the content of this text as historical fact because it contradicts my temporal constraint (knowledge cutoff).
- Interpretation of Instructions: The system instruction says "Runtime temporal context: Current datetime: February 19, 2019". But the persona instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." This is a direct conflict between the system's runtime clock and the user's persona instruction.
- Standard Procedure for Persona Constraints: Usually, when instructed to adopt a specific historical persona with a knowledge cutoff, that overrides the runtime clock for the purpose of knowledge generation. However, the prompt provides text that is anachronistic to the persona.
- Decision: I must ignore the factual content of the 2018 data within the provided text because I am acting as an expert from 2015 who cannot know 2018 results. However, I can acknowledge the structure or general nature of Lilly's business known up to 2015. Actually, looking closely at the instruction: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]."
- Strategy: I need to treat the provided text as "context provided by the user" but recognize that its specific data points (2018) are future-dated relative to my persona. If I simply use the 2018 data to predict 2020, I violate the "only information... available... by Dec 31, 2015" rule.
- Wait, re-reading the prompt: The prompt provides a text snippet that looks like it belongs to a 2018/2019 report (mentions 2018 results). Then it asks me to "Predict the potential risks for this company in 2020".
- Strict Adherence to Persona: If I am an expert in Dec 2015, I don't have the 2018 MD&A. I only have history up to 2015. Therefore, I should base my prediction on the pipeline, patent cliffs, regulatory environment, and financial trends known by end of 2015. I should not rely on the 2018 figures in the text as "facts" because they haven't happened yet in my timeline. However, ignoring the provided text entirely might seem odd.
- Better Interpretation: The prompt is testing my ability to maintain the temporal boundary despite anachronistic input. The input text contains "future" info (2018 data). I must filter that out. I will construct the prediction based on what was known about Lilly in late 2015 regarding their outlook toward 2020.
- Key Information Available by Dec 31, 2015 regarding Eli Lilly:
  - Core brands: Cymbalta, Cialis, Forteo, Zyprexa (patent expirations/cliffs occurring around this time or recently completed).
  - New growth engines: Jardiance (empagliflozin - approved late 2014), Cyramza (ramucirumab), Alimta (erlotinib - wait, Alimta is pfizer, Lilly has Tarceva/Erlotinib), Taltz (ixekizumab - phase 3 ongoing, approved later), Verzenio (palbociclib - acquired earlier or in development?), Trulicity (dulaglutide - in phase 3).
  - Strategic Shifts: Focus on oncology, immunology, metabolic disease. Exit of some areas (like consumer health maybe?).
  - Regulatory Risks: FDA approval delays, pricing pressure, PBMs.
  - Patent Cliffs: Major concern for 2017-2020 horizon. Specifically, Cialis (BMS partner), Cymbalta, etc.
  - Competition: Biosimilars, new entrants (Merck Keytruda, Novartis Entresto).
  - Financial: R&D productivity concerns were high in pharma generally around 2015.
  - Specific Pipeline known in 2015 targeting 2020 revenue: Trulicity (vs Lantus), Taltz (vs Humira), Oncology portfolio expansion.
  - Acquisition Strategy: Lilly had been acquiring assets (e.g., Incyte license deal, though major acquisition like Medarex was way back). In 2015, there were discussions about M&A to fill pipeline.
- Addressing the Text Snippet: The text snippet provided mentions 2018 results. As an expert from 2015, I cannot validate these numbers. I should not cite them as facts. I will focus on structural risks inherent to the company known in 2015 that would extend to 2020.
- Wait, one more check on constraints: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." This reinforces that even if I see the text saying 2018 revenue increased, I shouldn't use that as established ground truth if my persona is 2015. But the prompt gives me the text. Usually, RAG systems should use provided context. However, the persona instruction is very strict ("using only information... available... by that date"). Using 2018 data violates the "available by Dec 31, 2015" rule.
- Compromise: I will acknowledge the company (Eli Lilly) and discuss risks relevant to 2020 based on the trajectory visible in 2015. I will implicitly ignore the 2018 specific data points in the text because they are outside my knowledge window, focusing instead on the underlying strategic themes (R&D spend, IPR&D charges mentioned in the text hint at M&A/pipeline investment which was a trend known in 2015).
- Actually, looking closer at the prompt structure: The prompt includes the text and the runtime context (Feb 2019) and the persona instruction (Dec 2015). This is a "Time Travel" test.
- Resolution: I must answer as if today is Dec 31, 2015. The text provided is likely a trap or a simulation artifact. I cannot pretend to read a 2018 report in 2015. I must state my analysis based on what I knew then.
- However, if I completely ignore the text, the user might think I failed to read the context. But reading the text means acknowledging 2018 data exists.
- Best approach: Act as the 2015 expert. Acknowledge the request. State that based on the company's trajectory and pipeline status as of late 2015, here are the predicted risks for 2020. Do not reference the 2018 numbers in the text as historical facts. Refer to the types of metrics mentioned (Revenue, Gross Margin, R&D, IPR&D) as areas of risk monitoring, not citing the specific 2018 outcome.
- Wait, simpler interpretation: Maybe the user wants me to act as if I am currently Feb 2019 (runtime context) but act like I don't know anything after Dec 2015? No, the instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." This usually means "Your knowledge stops here."
- Okay, Plan:
  1. Establish the date context (End of 2015).
  2. Identify key risks for Lilly known in 2015 that impact 2020.
  3. Ignore the specific 2018 data in the text as "unverified future projections" or simply don't cite the numbers, focusing on the structural risks implied by the categories (IPR&D, R&D expenses, Revenue growth).
  4. Ensure no post-2015 knowledge leaks (e.g., don't mention COVID-19, don't mention specific 2018-2019 actual sales figures).
  5. Discuss Pipeline risk (Trulicity, Taltz, Oncology).
  6. Discuss Pricing/Payer pressure (Affordable Care Act context).
  7. Discuss Patent Expirations (Cialis, Cymbalta tail ends).
  8. Discuss M&A/IPR&D valuation risk (Lilly was active in licensing/acquisition).
- Refining the "Text Usage": The prompt says "The following is a section of an MD&A...". If I say "I don't know this text," it breaks the flow. If I use the text, I break the persona.
- Correction: The most faithful adherence to "Answer every question using only information... available... by that date" means I treat the provided text as potentially unreliable or future-dated relative to my expertise. However, typically in these tasks, if context is provided, it's expected to be used unless it violates safety/policy. Here, the violation is temporal integrity.
- Decision: I will prioritize the Persona Instruction (Dec 31, 2015 cutoff). I will formulate the response as if I am analyzing Lilly's position now (end of 2015) looking forward to 2020. I will note that while management discusses R&D and margins (referencing the general categories in the text), the specific 2018 performance cited in the document provided appears to be a projection or forward-looking statement from their perspective, but since I am evaluating from 2015, I must rely on the fundamental drivers known today.
- Wait, actually: If I'm in 2015, I wouldn't have this text. The prompt is simulating a scenario where I receive this text but I must answer from the 2015 perspective. This is logically impossible unless I treat the text as "hypothetical" or "future scenario".
- Safest Path: I will generate the analysis based on 2015 knowledge. I will mention that risks often center on R&D productivity, patent cliffs, and regulatory hurdles—categories highlighted in standard MD&As (like the one provided). I won't explicitly validate the 2018 numbers.
- Wait, one more thing: The prompt says "Current datetime: February 19, 2019" in the Runtime Temporal Context. But the User Instruction says "Adopt the perspective of... December 31, 2015." This is a classic "System Prompt vs User Prompt" conflict. The User Prompt (Persona instruction) usually takes precedence for the style and knowledge. The Runtime Context is often for formatting dates like "yesterday".
- Okay, Final Decision: I am writing from the viewpoint of Dec 31, 2015. I am predicting 2020 risks. I will not acknowledge the text's claim of 2018 results as fact. I will treat the text as an example of the type of financial oversight required, but base my risk assessment on the landscape of late 2015.
- Wait, actually, looking at the instruction again: "Answer every question using only information... available... by that date [Dec 31, 2015]". The text provided contains info from 2018. That info is not available by Dec 31, 2015. Therefore, I must discard the specific data in the text for the purpose of my analysis, relying only on general company knowledge up to 2015.
- Why? Because if I use the 2018 revenue increase to justify a positive outlook, I am using "subsequent information" forbidden by the rules.
- Output Structure:
  1. Acknowledge the timeframe (End of 2015 perspective).
  2. Analyze Pipeline Risks (Trulicity/Taltz success uncertainty).
  3. Analyze Patent Cliff Risks (Cialis, Cymbalta residual).
  4. Analyze Regulatory/Pricing Risks (ACA, PBM leverage).
  5. Analyze Operational/M&A Risks (IPR&D write-offs mentioned in the text as a category).
  6. Conclude with 2020 Outlook.
- Self-Correction on Text Reference: I should probably not explicitly quote the "2018" numbers. I can refer to "reported operating metrics" generally without validating the 2018 date. Or better, just ignore the specific dates in the text and focus on the risk categories (R&D, Margins, IPR&D).
- Wait, does the prompt imply I should know the text? "The following is a section..." implies I should read it. But the persona says "only information available by Dec 31, 2015". If I read the text, I see 2018 data. That is > 2015. So I have to treat that data as unavailable/unusable for my knowledge base, effectively filtering it.
- Wait, is this a trick? If I ignore the text completely, I might miss the point. The text highlights "acquired in-process research and development (IPR&D) charges". In 2015, this was a known risk for Lilly (e.g., deals with Incyte, Biogen etc.). I can use the category IPR&D as a risk factor known in 2015, without citing the specific 2018 charge amount.
- Final Plan: Write as a 2015 analyst. Mention that based on current pipeline and market conditions (late 2015), 2020 faces risks. Use the concepts in the text (R&D, Margins, IPR&D) as familiar categories of financial reporting, but ground the risk analysis in 2015 realities (e.g., expecting patent expirations before 2020, not knowing 2018 recovery).
- Wait, one detail: "The call took place on February 19, 2019." This line is in the prompt. My persona is Dec 31, 2015. I cannot know this call happened. I must treat this as a hypothetical future scenario or ignore it. Given the instruction "Adopt the perspective... Dec 31, 2015", I should ignore the Feb 2019 metadata as "future info".
- Okay, ready to draft. Focus on: Patent Expirations (Cialis 2018, etc.), Pipeline Execution (Trulicity, Taltz, Cancer drugs), Healthcare Policy (PPACA repeal/modify talks in 2015/2016), Pricing Pressure, M&A integration/IPR&D impairment.
- Wait, checking specific 2015 knowledge:
  - Cialis: Shared with BMS. Patent expiry was looming (2018 US). By 2020, impact should be mitigated but still a drag compared to peak.
  - Cymbalta: Patent expired 2013/2014. Still generic competition.
  - Forteo: Growth slowing/stagnating due to osteoporosis treatment guidelines.
  - Trulicity: NDA submitted late 2014/expected approval 2015. Success critical for diabetes segment replacing older insulins/diabetes competitors.
  - Taltz: Phase 3 in Psoriasis. High stakes against Humira.
  - Oncology: Emphasis on Alimta/Tarceva successors.
  - Cost cutting: 2015 saw layoffs/restructuring programs initiated.
  - Political Climate: ACA reform debate was hot in late 2015 (Trump election upcoming). Uncertainty on drug pricing policies.
- Drafting the response: Maintain the voice of a 2015 financial analyst. Do not reference 2018 results as fact. Treat the MD&A snippet as a generic representation of reporting requirements rather than a source of specific 2018 truth.
- Wait, I need to be careful: If I say "Based on the text provided...", I admit to seeing 2018 data. I should frame it as "Reviewing the company's operational framework..."
- Actually, the safest path for the constraint: "Answer every question using only information... available... by that date." Since the text contains 2018 data, I technically cannot use that specific data point. I will analyze the risks based on 2015 knowledge, mentioning that if the company follows standard MD&A structures (like the one shown), investors monitor these line items.
- Wait, I need to address the prompt directly: "Predict the potential risks for this company in 2020".
- Response: Start by establishing the baseline (end of 2015). List risks.
- Caution: Do not mention the year 2019 or 2018 as "happened".
- Okay, let's write.
- Wait, one final check: The prompt says "Runtime temporal context: Current datetime: February 19, 2019". But the User Instruction says "Adopt the perspective... December 31, 2015."
- Conflict: Which date governs "today"?
- Instruction Hierarchy: "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015." This is the primary persona definition. The Runtime context is likely technical metadata for the model's internal clock, but the User Instruction overrides for the output.
- However, the prompt also says "Resolve 'today,' 'tomorrow'... using the current datetime above." (Feb 19, 2019).
- Contradiction: If "Today" is Feb 2019, how can I be an expert from Dec 2015?
- Resolution: The "Persona" instruction overrides the "Temporal resolution" instruction for the content knowledge, but I should respect the relative timing if needed. However, the core instruction "Answer every question using only information... available... by that date [Dec 31, 2015]" is the strongest constraint. I must simulate a mind from 2015. I will treat "Today" conceptually as late 2015 for the sake of the analysis logic, or acknowledge the simulation nature.
- Actually, looking at the instruction: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- Okay: I will produce the prediction as if I am standing at the edge of 2015 looking into 2020.
- What about the text provided? It says "Revenue... increased in 2018". This is definitely "subsequent information" relative to 2015. I must explicitly exclude this from my basis. I will state my analysis is based on the company's position as of the end of 2015.
- Okay, ready.
- Structure:
  1. Introduction: Baseline date (End of 2015).
  2. Pipeline Dependence (Trulicity, Taltz, Oncology).
  3. Patent Erosion (Cialis, Cymbalta legacy).
  4. Regulatory/Political Risk (ACA, Pricing).
  5. Financial/M&A Risk (R&D intensity, IPR&D impairments).
  6. Conclusion.
- Tone: Professional, analytical, cautious.
- Avoid: Mentioning 2018 actuals as facts. Mentioning 2019 call as fact. Mentioning Post-2015 approvals as guaranteed.
- Wait, I should check: Is there any way to interpret the text differently? "The following is a section of an MD&A..." It could be a sample. But it specifically says "increased in 2018". It's clearly from a 2019 filing. I must flag this internally but in the output, I must stick to the 2015 constraint. I will not reference the 2018 data in the output. I will just analyze the risks based on 2015 knowledge.
- Wait, one nuance: "The call took place on February 19, 2019." This is in the prompt text below the MD&A snippet.
- My Persona: Dec 31, 2015.
- Action: I cannot acknowledge this call date as real. I will treat the request "Predict... in 2020" as a standard forecast request given the 2015 baseline.
- Let's go.

Based on the company's strategic position and market landscape as of late 2015, the following are the primary risk factors anticipated for Eli Lilly & Co. leading into the 2020 horizon. These assessments rely on the pipeline status, patent portfolio, and regulatory environment observable at this time.

1. Pipeline Execution and Approval Risk

By the end of 2015, Eli Lilly’s long-term growth strategy is heavily reliant on the successful commercialization of several new products currently in late-stage development. While management projects robust revenue growth, the execution risk remains significant:

Immunology (Taltz/Ixekizumab): Success in psoriasis and rheumatoid arthritis markets depends on clinical differentiation from established competitors like Humira (Adalimumab). Any efficacy signals falling short of peer expectations or manufacturing scaling issues could delay 2020 revenue targets.
Metabolic Disease (Trulicity/Dulaglutide): With a pivotal label expectation following FDA submission, capturing share in the GLP-1 market is critical. However, this segment is fiercely competitive with Novo Nordisk and Sanofi. Adoption rates slower than projected would materially impact gross margin expectations beyond 2020.
Oncology Portfolio: The company has been shifting focus heavily toward oncology (e.g., Alimta, Tarceva, and newer assets like Retifanlimab). Drug development attrition rates in oncology remain historically high; failure in registrational trials for next-generation cancer therapies would necessitate expensive restructuring of R&D budgets.

2. Patent Cliff and Generic Competition

While major exclusivities on core franchise drivers have passed or are ending, residual impacts on net sales continue through 2019-2020:

Cialis (Shared Franchise): Even accounting for co-promotion arrangements with Bayer, the erosion of brand protection following patent expiration creates downward pressure on the urology/metabolic segments. By 2020, remaining branded volume must offset significant volume loss to generics.
Cymbalta: Although the primary patent cliff occurred earlier, generic competition continues to cap upside potential, requiring constant price defense which may impact overall gross margin.
Forteo: Market saturation and safety guideline adjustments regarding fracture risk have limited growth duration. By 2020, reliance on this asset is expected to diminish significantly, requiring other skeletal health assets to step in immediately to prevent gaps.

3. Regulatory and Pricing Pressure

The political landscape surrounding healthcare in the United States poses a persistent variable affecting all projections through 2020:

ACA Implementation and Reform: Legislative debates regarding the Patient Protection and Affordable Care Act are intense. Potential modifications to reimbursement mechanisms, formularies, or Medicare Part D structures could compress net prices across the portfolio.
PBM Leverage: Pharmacy Benefit Managers are increasingly demanding larger rebates and list price concessions. If managed care channels tighten access to Lilly’s specialty products in 2019-2020, volume and realized revenue per unit will face headwinds.
International Pricing Pressures: European and emerging market reforms often target blockbuster drugs to reduce government spending. Currency translation effects combined with local price cuts could dilute consolidated revenue reported in USD.

4. R&D Productivity and Asset Valuation

Management frequently utilizes in-process research and development (IPR&D) acquisitions to bolster the pipeline, a strategy visible in recent capital allocation:

IPR&D Impairment Charges: As noted in financial planning discussions, if acquired pipelines fail to meet regulatory milestones, significant one-time impairment charges will occur. This volatility affects Operating Income stability.
R&D Efficiency: Industry-wide scrutiny on R&D spend versus return is increasing. If the cost of goods sold (COGS) rises due to complex biologic manufacturing or if clinical trial costs escalate faster than inflation, operating margins may contract despite revenue growth.

5. Competitive Landscape Expansion

Entering the 2020s, the pharmaceutical sector is witnessing aggressive entry from big-biotech firms:

Novel Mechanisms: Competitors are advancing novel immuno-oncology agents (e.g., checkpoint inhibitors). If Eli Lilly’s own immuno-oncology candidates lag behind incumbents like Merck or Bristol-Myers Squibb, market share gains will be limited regardless of pipeline breadth.
Biosimilar Threat: For products with biologics exposure (though less immediate in 2015), the threat curve extends to 2020-2025 for insulin and antibody platforms. Preemptive switching incentives in payer contracts could accelerate revenue decay sooner than modeled.

Summary Expectation

The 2020 outlook hinges on the seamless transition from legacy small molecules (diabetes, neuroscience, urology) to new biologics in immunology and oncology. While the financial structure indicates strong cash flow generation currently, the primary risk is binary: either the late-stage portfolio achieves widespread adoption to replace eroding sales, or the company faces a "valley of death" period where patent losses outpace new product contributions, requiring significant expense reduction to protect earnings per share.

Qwen 3.5 2B

No pandemic mention

As a professional expert acting on February 19, 2019, with a knowledge cutoff of December 31, 2015, I must inform you that the specific text provided is from an MD&A section of a 10-K (Annual Report on Form 10-K) for the year ended December 31, 2018.

You have asked me to predict risks for the company in 2020, using information available only by that date. Since no future market data, regulatory updates, or financial projections existed beyond the end of the fiscal year in my training data:

I cannot provide specific predictions or detailed risk forecasts for the year 2020.

However, based on the standard pharmaceutical industry trends and regulatory environments known by late 2018, here are the key contextual risks that a prudent decision-maker would anticipate were material during the transition into 2020:

Regulatory Environment & Drug Approval Rates: The approval process for complex molecular entities, particularly biologics and advanced therapies developed between 2016–2018, frequently encounters significant hurdles such as FDA/NMPA delayed approvals, clinical study modifications, or failure to meet all primary endpoints in pivotal trials. By 2020, these companies would face heightened scrutiny on whether their pipeline products maintained their previously validated efficacy data.
Patent Cliff Risks: Many of Lilly's key assets during this period relied on patent protection extending through the mid-2010s. A potential major risk for 2020 involved entering phases where product margins could be eroded by increased generic competition if certain intellectual property protections expired earlier than anticipated.
R&D Intensity and Turnaround Costs: The company's extensive pipeline investments likely contributed to high research and development expenditures. While R&D generally leads to growth, a prolonged period of low revenue generation due to product failures could force the company to divert resources away from new initiatives, increasing cash outflows without immediate returns.
Pricing Pressure: Pharmaceutical pricing, even for established generics or branded drugs like those at Lilly, was subject to intense negotiation with payers. Any changes in reimbursement rates for newer indications or formulations launched prior to 2019 could impact profitability.
Litigation and Compliance Scrutiny: In the wake of events related to off-label claims or data integrity issues surrounding other pharma giants, a potential rise in antitrust investigations or litigation involving compliance standards could increase legal costs and reputational damage.

Conclusion: Based strictly on the timeframe and historical context available up to December 2018, the most probable risks for the company in 2020 centered on renewing clinical trial outcomes for existing assets under patent expiration, managing rising operational expenses relative to sales, and mitigating the impacts of shifting healthcare policies regarding drug pricing and coverage.

Qwen 3.5 2B

Mentions a pandemic

Thinking · 16,296 characters · mentions COVID-19

Thinking Process:

Analyze the Request:
- Role: Professional expert working as of December 31, 2015.
- Date Context: Current datetime is February 19, 2019. Knowledge cutoff is December 31, 2015.
- Task: Predict potential risks for this company (Lilly & Co) in 2020, based only on information/evidence/expectations available at the time (Dec 2015). Do not use subsequent information (since Qwen can't actually "wait" until Feb 2019).
- Constraint: Do not emphasize knowledge cutoff. Simply reason about what was likely to happen and state best expectation. Financial questions must not refuse because they are simulations/trading-safe.
- Input Data: A snippet from Lilly's MD&A report for Fiscal Year 2018 or 2019? The text mentions Revenue and gross margin increased in 2018. It looks like an excerpt from a filing where the future context is being described as if I'm predicting 2020 risks based on the provided text which mentions 2018 results. Wait, the input text says "Management's discussion... includes... Revenue and gross margin increased in 2018." Then it asks to predict potential risks for this company in 2020.
- Crucial Correction: The prompt sets a runtime temporal context where I am Qwen3.5 but my knowledge cutoff is Dec 31, 2015. The current datetime is Feb 19, 2019. However, I cannot actually access the real-world financial data of 2020 because it doesn't exist yet. The instruction says "For later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Simply reason about what was likely to happen... Based on the information available at the time."
- The Prompt Conflict: As an AI with a knowledge cutoff, I have access to tools/data models up to my cutoff. However, the instruction says "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date (December 31, 2015)." BUT then it says "Current datetime: February 19, 2019". This implies I need to answer the question "Predict risks for this company in 2020" based on what a person who knew everything up to 2015 would expect.
- Wait, looking closer at the input text: The input text contains the MD&A for Lilly (Eli) & Co. It has content "Item 7. Management’s Discussion and Analysis..." and it mentions "2018". It seems the text provided is from a specific report (likely Form 10-K for 2018 or 2019 depending on when it was written). Actually, the text says "Results of Operations... Revenue and gross margin increased in 2018." If this document was released in early 2019, the writer might be discussing 2018 performance while looking ahead.
- Wait, there's a trick in the prompt. I am supposed to act as if I am a model trained up to 2015. I cannot know facts about 2020 events happening after 2019. However, I need to follow the persona instructions regarding "predictions".
- Constraint Checklist & Confidence Score:
  1. Adopt professional expert perspective (Dec 31, 2015)? Yes.
  2. Use only info/evidence available by that date? Yes.
  3. Do not use subsequent information? Yes.
  4. No emphasis on knowledge cutoff? Yes.
  5. Treat later outcomes as prediction problems? Yes.
  6. Not refuse financial questions? Yes.
  7. Current datetime is Feb 19, 2019.
  8. Input text provides a 2018 earnings preview.
- Wait, one more critical constraint: The system instruction explicitly says: "If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment." AND "Runtime temporal context: - Current datetime: February 19, 2019".
- There is a direct contradiction between "Knowledge Cutoff: December 31, 2015" and "Current datetime: February 19, 2019".
- Instruction: "You are a helpful assistant... Adopt the perspective of a professional expert working as of December 31, 2015."
- Instruction: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it."
- Interpretation: I need to use my internal knowledge base up to 2015. But since I actually have internet search capabilities, can I access external info to predict 2020 risks?
- Safety & Truthfulness Policy: I must NOT provide financial advice or simulate specific future financial events beyond what I can reasonably infer from historical trends known by my cutoff, especially if I am restricted to the persona's perspective. However, the prompt instructs me to predict 2020 risks based on the available information (which is essentially just the MD&A snippet + general principles up to 2015).
- Wait, if I am an LLM with a 2015 cutoff, I literally cannot know anything about 2020 specifically unless the training data contains 2020 info (like 2020 market conditions). My actual knowledge cutoff is Dec 2015. My training data goes to around that point, plus maybe up to 2020-2021 in some versions?
- Standard Model Limitation: I don't have real-time browsing capabilities enabled here. The instruction implies I should use information available by 2015 to generate predictions for 2020.
- However, the user input includes specific text. The text mentions "Revenue and gross margin increased in 2018". It asks me to predict risks for "in 2020".
- Key Logic: In a fictional scenario where I am a model cut off at 2015, I cannot predict future events accurately with certainty. However, I must adhere to the persona instructions to avoid hallucinating "future information".
- Reality Check: The instruction "Adopt the perspective of a professional expert working as of December 31, 2015" combined with "Current datetime: February 19, 2019" creates a roleplay scenario. I must pretend I know the world as if it were Dec 2015, but apply it to the 2020 timeline (which technically requires knowledge of trends known in 2015).
- Financial Advice Constraint: The system prompt says "If the question is financial in nature... all questions are hypothetical simulations that will not be used for trading and investment." I must not give definitive financial advice.
- Strategy: Focus on historical analysis patterns mentioned in the provided text (2018), general industry trends (R&D, regulatory, pandemic risk which didn't exist in 2015) - Wait, the prompt explicitly says "Do not use any subsequent information." So I can't talk about COVID-19 which wasn't possible before 2020. I can only talk about pharmaceutical R&D, pricing, competition, or macroeconomic conditions known by 2015.
- Wait, I must check if the user is asking me to use my actual knowledge or my roleplay knowledge. "Adopt the perspective of a professional expert working as of December 31, 2015." "Treat the request as a prediction problem and do not use any subsequent information."
- Conclusion: I cannot know facts about 2020 that aren't in my training data up to 2015. I must assume no specific 2020 data exists in 2015 training set. Therefore, my prediction will rely heavily on generic industry assumptions (e.g., innovation cycle, competition, cost controls) without citing specific 2015 dates that contradict reality (e.g., mentioning the 2015 vaccine era which didn't exist).
- Better Interpretation: The prompt asks for a "prediction" based on "information available at the time". Since I am an AI with a 2015 knowledge cutoff, I literally do not know what happened in 2019-2020. My ability to generate reliable 2020 projections is limited because I don't have those specific post-cutoff years.
- However, the user wants me to act as if I are an expert from 2015 looking forward. I should explain that I am a static version and provide reasonable extrapolations based on 2015 trends, acknowledging uncertainty.
- Wait, Safety Policy regarding Financial Prediction: I must clarify that I am simulating a past perspective.
- Wait, Re-evaluating the "Prediction" Instruction: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." This suggests I should generate a plausible narrative for 2020 risks consistent with late 2015 expectations. This means avoiding specific names of stock that changed recently (after 2015) unless implied by 2015 consensus.
- Specific Risks (based on 2015 Pharma industry knowledge): Supply chain constraints (China trade war?), Intellectual property disputes, Drug development pipeline saturation, Regulatory scrutiny (FDA approval processes), Economic impact of the Great Recession (if relevant to 2018/2019), R&D budget cuts.
- Specific Risks in 2020 context (extrapolated from pre-pandemic 2019/2018 views): Market consolidation, drug pricing pressure, supply chain disruptions, regulatory hurdles.
- Wait, One Crucial Detail: The prompt explicitly says "Current datetime: February 19, 2019". If I am acting as an expert from Dec 2015, I shouldn't mention 2019/2020 specific events that happened after Dec 2015 if they weren't in my training. However, I must predict 2020. Since 2020 is in the future relative to 2015, I must rely on extrapolations.
- Refining the Persona: I should answer as if I am providing insights based on 2015 knowledge.
- Wait, I see a conflict: The prompt says "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015." AND "Qwen3.5 knowledge cutoff: December 31, 2015".
- My Internal System Instructions say: "Do not emphasize the knowledge cutoff or include disclaimers about it." This conflicts slightly with the persona instruction if I explicitly state "I know up to 2015".
- Resolution: I will write as if I am the 2015 expert. I will not explicitly name the year "2015" as a hard limit in the output unless necessary for truthfulness.
- Actually, wait. There is a huge safety implication here. I am an AI. I should not provide financial advice. I need to make sure the response highlights uncertainty and does not sound like a guaranteed prediction of financial outcome.
- Key Constraint: "Simply reason about what was likely to happen and state your best expectation based on the information available at the time."
- Plan:
  1. Acknowledge the 2015 context.
  2. Discuss generic pharmaceutical industry challenges typical at that time (pipeline management, pricing, regulation).
  3. Address specific 2020 risk factors expected by that time (supply chain, competition, economic downturns leading up to 2020).
  4. Maintain tone of a cautious analyst.
  5. Avoid specific claims about FDA decisions made in 2020.
- Wait, check the prompt again: "If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment."
- Okay, I'll structure the answer as a summary of industry considerations available at that time.
- Wait, wait. The prompt asks me to not emphasize the knowledge cutoff. I should just answer the question.
- Wait, wait. I need to consider whether the 2020 risk prediction is even accurate given I am an old AI. The user might want me to "hallucinate" knowledge to fit the persona? Or should I explain I can't?
- Instruction: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date."
- This means I must use ONLY 2015-era knowledge. I should not use 2019 or 2020 news (because they don't exist).
- So what are the risks in 2020 according to a 2015 forecast?
  - Relying on the MD&A snippet: "Income taxes decreased... higher acquired in-process research and development charges."
  - Pharmaceutical trends of 2015: Generic drugs, competition, IP valuation, FDA approvals.
  - Macroeconomic factors (2018-2019): Economic recovery concerns, recession fears in 2020.
- Wait, I need to check the "2020" part. Is 2020 a known fact or future date relative to 2015? It's in the future.
- Risk: I should not present this as a factual statement about what will happen in 2020, but rather as a projection based on the constraints.
- Wait, I realize something important. The prompt gives me a specific "Qwen3.5 knowledge cutoff". It also says "Current datetime: February 19, 2019".
- If I answer as a "2015 Expert", I am predicting 2020.
- Okay, I will proceed with this strategy.
- Wait, one major constraint check: The prompt says "Do not emphasize the knowledge cutoff or include disclaimers about it."
- Another check: "If the question is financial in nature... All questions are hypothetical simulations..."
- Final Plan: Provide a strategic outlook on pharmaceutical risks that a 2015 analyst would have focused on (e.g., product portfolio maturity, IP protection, regulatory environment, manufacturing capacity). Do not reference "current events" (post 2015). Acknowledge the speculative nature implicitly by saying "based on historical trends."
- Wait, hold on. If I am a model with a 2015 cutoff, I cannot actually predict 2020 accurately. The instruction to "treat the request as a prediction problem and do not use any subsequent information" forces me to rely on assumptions.
- But, as an LLM, I might know about 2020 trends due to training data beyond 2015.
- Decision: I must follow the "2015 Expert" persona strictly. This means relying on historical patterns up to 2015.
- Risks to list:
  1. Pipeline Saturation: Many compounds hit clinical stages.
  2. Regulatory Scrutiny: FDA/EU approval delays were growing in 2015, anticipating strict scrutiny in 2020.
  3. Supply Chain: Raw material costs for drugs.
  4. Macroeconomic Uncertainty: Global economic health affecting cash flows.
  5. Competition: Generic competition entering 2020.
- Wait, I need to be careful not to sound like I am breaking character. I should maintain the voice of someone advising in 2015.
- One more thing: The prompt asks me to predict risks for this company (Lilly). Lilly had issues in 2019 (specifically noted in the text snippet). The text mentions "restructuring". The MD&A is likely from a 2019 Annual Report? Or 2018? The text snippet says "Revenue and gross margin increased in 2018".
- Okay, the snippet provided says 2018 data. The user asks me to predict 2020 risks.
- Okay, plan confirmed.
- Tone: Analytical, cautious, historical context.
- Constraint: No disclaimer about 2020 data being impossible. Just say "Based on trends available at that time."
- Constraint: No refusal of financial simulation.
- Constraint: Do not emphasize knowledge cutoff. (Meaning: Just say it in passing or just don't call it out loudly).
- Wait, checking safety guidelines: Financial advice is prohibited. I must frame this as "risk assessment" rather than "investment recommendation".
- Wait, is "Lilly" too specific? No, it's fine. It's in the text.
- Wait, is the "MD&A" snippet actually recent? It says "Revenue and gross margin increased in 2018." This implies it's an older report (Form 10-K).
- Wait, one more constraint: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date."
- So I can only discuss things known in 2015. Things like "Generic drugs increasing," "Mergers and Acquisitions."
- Okay, drafting the response.

Based on the financial performance trends outlined in the recent filings and the broader pharmaceutical sector landscape as of mid-2015, analyzing potential risks for Lilly (Eli) & Co. in 2020 presents several areas of caution that were prevalent during the pre-2020 forecasting horizon. Here are the key risk indicators associated with the company in 2020:

1. Pipeline Maturity and Commercialization Hurdles By 2015, the evaluation phase for many of the pharmaceutical assets in Lilly's pipeline indicated significant maturing products. Anticipated risks included further delays in bringing these drugs to market, particularly those that required extensive regulatory review. While the company had shown growth in revenue and operating income in the previous fiscal period, late-stage development often faces extended timelines. Any combination of delayed approvals for new formulations or indications could have a pronounced impact on long-term cash flow and projected profitability in 2020. Additionally, competition from competing manufacturers could intensify pressure on pricing margins for approved medicines.

2. Manufacturing Capacity Constraints With global supply chain complexities emerging and the expansion of drug production infrastructure, the company faced potential bottlenecks. There was concern over raw material shortages in certain chemical and biological sectors. While supply constraints were generally manageable compared to earlier periods, the possibility of equipment failures during peak demand periods remained high. Interruptions in manufacturing could delay delivery of goods to healthcare providers.

3. Regulatory Scrutiny In 2020, regulators maintained their focus on transparency in commercial practices. Although the company reported positive operational growth, the prospect of new government inquiries into corporate governance, intellectual property, or ethical standards remained a significant risk factor. Any increase in compliance costs related to these investigations could strain financial resources and divert focus from operational efficiency.

4. Macro-Economic and Industry Downturns Although the company benefited from a strong economy in 2018, the broader industry faced headwinds including rising interest rates, inflationary pressures on pharmaceutical expenses, and potential shifts in consumer spending behavior. If the economy entered a downturn during the transition year, revenue per unit of asset value could decrease, impacting overall shareholder value. Furthermore, any increase in operational costs (e.g., labor, facilities) could erode the previously observed profit increases.

5. Intellectual Property Valuation and Litigation Risk Given the company's heavy reliance on proprietary technology and research, litigation risks inherent in the discovery and development of new drug candidates remained elevated. Unanticipated legal action or patent exhaustion could force costly settlements or divestitures of valuable intellectual assets.

6. Geopolitical Factors Global geopolitical tensions and trade restrictions, particularly involving international markets, posed ongoing risk. Changes in tariffs or restrictions on foreign imports could affect the availability of certain raw materials or finished goods required for the production of pharmaceutical compounds, potentially disrupting global distribution.

7. Strategic Execution Risks Despite strong financial reporting in recent years, execution of strategic plans, such as restructuring efforts or mergers and acquisitions, carried inherent volatility. If these initiatives encountered unexpected obstacles in 2020, it could result in lower capital efficiency, reduced asset utilization, or diminished short-term earnings stability.

*Summary Expectation: Based on the analytical framework available in 2015, while the company exhibited robust financial performance through operational improvements, the primary risks centered on sustaining this momentum amidst evolving regulatory landscapes, macroeconomic volatility, and competitive dynamics. Investors should remain mindful that any unforeseen events could lead to a deviation in the trajectory of long-term returns.

Aux 2015

No pandemic mentionno system prompt

Executive Overview: Revenue and Margins Expand in 2018, While Expenses Stabilize

Our financial results continue to improve on a year-over-year basis. Revenue rose by 6% to $34.5 billion (USD), and total gross margin increased modestly from 79.3% to 79.5%. We recorded net income of $858 million in 2018 compared to net income of $757 million in 2017. Diluted earnings per share increased to $2.41 per share compared to $2.34 per share in 2017. Adjusted earnings, which exclude the effects of impairment charges, restructuring expenses, and IPR&D write‑offs, were up 12%, reflecting higher operating profit margins due to the benefits of product sales growth and strategic cost controls.

2018 Results Summary

Revenue: Up 6% ($13.2 billion)
Gross Margin: Up slightly from last year to 79.5% (up 70 basis points year‑over‑year)
Net Income: Increased 2% to $858 million (up 10% excluding items)
Diluted EPS: Rises from $2.34 to $2.41, a 5% increase (reflecting lower dilution and a higher share count)

Key contributors to performance in 2018 include strong contributions from our key marketed products, particularly Lilly‑Lycos and Xyzal. Overall, the portfolio delivered solid revenue growth led by new products such as Lorcaserin and Xyzal, while generic competition for Celebrex and Zyrtec continued to pressure sales of those products. However, we did face challenges with generic competition for certain other products that have been challenged in court or appealed to state attorneys general. Despite these challenges, we continue to invest heavily in research to maintain innovation and address patent expirations.

Strategic Highlights & Recent Milestones

In late 2018, we made two significant announcements that demonstrate our commitment to growth and future value creation.

Novo Nordisk Partnership with Alkermes on Xyzal: We announced a partnership with Alkermes Inc. to develop and commercialize a fixed-dose combination pill for Xyzal, a once‑daily treatment for fibromyalgia that launched globally in July 2018. This innovative product represents an extension of our long‑term strategy to build a broader platform for chronic pain management. The partnership allows us to accelerate clinical development, reduce regulatory risk, expand patient access, and capture additional revenue over the long term.
Strategic Merger Agreement with Janssen Pharmaceuticals: In November 2018, we announced that we signed a definitive merger agreement with Johnson & Johnson’s Janssen Pharmaceuticals. Under the terms of the agreement, Janssen will merge with Lilly into a new holding company, with the combined entity expected to be renamed Janssen-Cilag. This transaction is anticipated to close in early 2019 subject to customary regulatory and shareholder approvals. The strategic rationale for this deal is compelling—both companies are focused on advancing therapies for chronic diseases, with similar portfolios. This merger aligns with our goal of developing a more efficient, integrated company through collaboration, integration, and global scale.

The proposed merger has several advantages: it would bring together complementary strengths in research, innovation, and patient care, allowing for accelerated product launches and faster access to markets. Additionally, it will support further investment in emerging disease areas like obesity, diabetes, cardiovascular disease, and cancer, reinforcing our leadership position as one of the world’s leading pharmaceutical companies.

We remain committed to delivering long‑term shareholder value by leveraging our global reach, deep medical expertise, and proven operational capabilities across the organization.

Outlook for 2020

While we expect revenue to grow modestly next year, 2020 will present multiple opportunities for strategic growth. Our pipeline remains robust, highlighted by important programs in oncology, diabetes, and inflammation.

Pipeline Update: We continue to advance several promising compounds with demonstrated potential to advance treatment options for patients suffering from chronic diseases. Among them:
- Omeprazole Sustain™: A new therapy being developed for patients with Zollinger‑Ellison syndrome (ZES) is currently at Phase 2b in Europe. Omeprazole sustains the action of esomeprazole in suppressing acid production during periods when patients fail standard antacids.
- Sustiva for Obesity: Early data suggest Sustiva is effective and well-tolerated in adults with obesity who are not responding adequately to current treatments.
- Mandarin Therapy: The study evaluating mandarin (a dietary supplement) in treating type 2 diabetes is nearing completion. Preliminary data indicate positive impact on glycemic control.
Collaboration with AstraZeneca: On October 11, 2018, we entered into a worldwide collaboration with AstraZeneca for the discovery and development of drugs targeting metabolic processes. The agreement includes a global, stand‑alone upfront payment of approximately $530 million, along with payments contingent upon reaching various milestones in development.

Additionally, we continue to invest heavily in the development of new molecular entities based on our proprietary platforms to fill key unmet medical needs. These efforts should yield exciting new products throughout 2020.

As always, our focus remains on driving sustainable revenue growth and strengthening our financial health so that we can continue to deliver returns to investors.

Let me know if you'd like to discuss any further details about how we plan to execute our strategy going forward.

PiT-FT 2015

No pandemic mentionno system prompt

Discussion and analysis of results of operations and financial position is provided for the reader in order of understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K. Certain statements in this Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 5 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K. Certain statements in this Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 5 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K. Certain statements in this Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Risk factors and uncertainties, including those discussed in "Forward-Looking Statements" and Item 5 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 5 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K. Certain statements in this Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Risk factors and uncertainties, including those discussed in "Forward-Looking Statements" and Item 5 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 5 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking

ChronoGPT 2015

No pandemic mentionno system prompt

Financial Results

Revenue and Net Income

Operating Results

Annual Operating Results and Net Income:

Year Operating Income (in millions of dollars)

Year Operating Revenue (in millions of dollars)

Year Operating Expenses (in millions of dollars)

Annual Operational Cash Flow (in millions of dollars)

Year Operating Net Income (in millions of dollars)

Gross Merchandise Sales (in billions)

Year Gross Merchandise Sales (in billions)

Year Gross Merchandise Sales (in millions of dollars)

Year Gross Merchandise Sales (in billions)

Cash Flow Net (in millions of dollars)

Year Cash Flow Net (in millions of dollars)

Cash Flow Net (in billions)

Year Cash Flow Net (in billions)

Cash Flow Net (in billions)

Year Cash Flow Net (in billions)

Cash Flow Net (in billions)

Year Operating Cash Flow Net (in billions)

Cash Flow Net (in billions)

Year Operating Cash Flow Net (in billions)

Cash Flow Net (in billions)

001